

SUPPLEMENTARY DATA

Supplementary Table 1. Clinical characteristics of patients from which kidney biopsies were collected and analyzed by Affymetrix microarray gene expression profiling

	DKD (T2D)	Living Donors
Total number of patients	70	32
Gender (F / M)	52 F / 18 M	15 F / 17 M
Age (years)	45 ± 10	48 ± 12
Urine albumin/creatinine ratio (mg/g)	292.2 ± 967.3	NA
Serum creatinine (mg/dl)	0.74 ± 0.18	0.80 ± 0.26
Serum cholesterol (mg/dl, n = 57)	169 ± 37	NA
HbA _{1c} (%)	9.3 ± 2.1	NA

Data are presented as mean ± SD. NA: non available

Supplementary Table 2. Clinical characteristics of five patients with DKD from which two consecutive serum samples where collected 6 years apart.

	Time 0 (n=5)	Time 1 (n=5)
Age	44±13	50±13
Gender	M/F (5/0)	M/F (5/0)
Diabetes duration	25±17	31±18
HbA _{1c} (%) (mmol/mol)	8.1±1.4 65±16	7.8±1.4 63±15
Serum creatinine (mg/dl)	0.84±0.09	1.13±0.16
eGFR	109±14	75±11
Total chol (mg/dl)	229±40	165±29
HDL chol (mg/dl)	56±10	54±14
Triglyceride (mg/dl)	160±40	103±47

Data are presented as mean ± SD.

SUPPLEMENTARY DATA

Supplementary Figure 1. Simvastatin does not protect podocytes from changes observed after exposure to DKD+ sera. (A) Representative confocal images of phalloidin stained normal human podocytes exposed to DKD+ sera when compared to C and DKD- sera in the presence or absence (control) of simvastatin.

